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The evidence base for behavioral activation (BA) as a frontline treatment for depression is 
grounded in individual delivery. No valid previous meta-analytic reviews of BA delivered in 
groups have been conducted.  This study therefore examined the efficacy and acceptability of 
group BA drawn from clinical trial evidence. Randomized controlled trials of group BA were 
identified using a comprehensive literature search. Depression outcomes at post-
treatment/follow-up, recovery and drop-out rates were extracted and analyzed using a 
random-effects meta-analysis. Treatment moderators were analyzed using meta-regression 
and subgroup analyse. Nineteen trials were quantitatively synthesized.  Depression 
outcomes post-group BA treatment were superior to controls (SMD 0.72, CI 0.34 to 1.10, 
k=13, N=461) and were equivalent to other active therapies (SMD 0.14, CI -0.18 to 0.46, 
k=15, N=526). Outcomes were maintained at follow-up for group BA and moderators of 
treatment outcome were limited. The drop-out rate for group BA (14%) was no different to 
other active treatments for depression (17%). Further research is required to refine the 
conditions for optimum delivery of group BA and define robust moderators and mediators of 
outcome. However, BA delivered in groups produces a moderate to large effect on depressive 
symptoms and should be considered an appropriate front-line treatment option.  
 








When a person is depressed, a widely observed symptom is behavioral avoidance, 
withdrawal and reduced activity, with these behavioral symptoms often contributing to the 
maintenance of low mood (Curran, Ekers, Mcmillan, & Houghton, 2012).  Given this 
behavioral component, behavior change has long been a treatment target in the psychotherapy 
of depression.  The initial treatment sessions of cognitive therapy for depression (Beck, Rush, 
Shaw, & Emery, 1979) focus on behavioral techniques (i.e., activity scheduling) in order to 
initially lift mood, with evidence of associated early change in depressive symptoms (Ilardi & 
Craighead, 1994). Purely behavioral treatments for depression that share core techniques 
around increasing activation and eliciting positive reinforcement have existed since the 
1970’s.  
Treatments can be clustered under four models: Lewinsohn’s pleasant events, 
focusing on increasing access to pleasant events through activity scheduling (Lewinsohn, 
Sullivan, & Grosscup, 1980); Rehm’s self-control therapy, comprising three key elements of 
self-monitoring, self-evaluation and self-reinforcement (SCT; Rehm, 1984); Martell’s 
contextual behavioral activation (BA), derived from the initial BA segment of Beck’s 
cognitive behavioral therapy (CBT) for depression manual (Martell, Addis, & Jacobson, 
2001); and Lejuez’s behavioral activation treatment for depression (BATD; (Lejuez, Hopko, 
& Hopko, 2001). Early versions of BA applied relatively simple methods (e.g., pleasant 
events), whilst more recent developments of BA (e.g., contextual BA) are more complex. 
Core differences revolve around the activation approaches used to increase response-
contingent positive reinforcement. SCT elaborates on the original pleasant events model by 
emphasizing the role of self-control in attenuating negative consequences of depression and 
using self-management skills to reinforce positive behavior change. BATD further expands on 
the pleasant events approach by relating goals to major life areas (relationships, hobbies etc.) 
and using activity hierarchies to focus on rewarding achievement of activity goals. 
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Contextual variants also incorporate values work, but have an additional emphasis on the 
function of avoidance and approach behaviors as a key strategy for overcoming depression 
(Kanter et al., 2010). 
A central aspect of the BA evidence base is Jacobson’s component study (Jacobson et 
al., 1996), as this emphasized that the cognitive elements of CBT were not necessary to 
achieve a good outcome with depressed patients. This evidence enabled BA to emerge as a 
stand-alone depression treatment (Martell et al., 2001).  Subsequent BA outcome research has 
demonstrated that BA is an effective treatment, producing equivalent outcomes to CBT 
(Cuijpers, van Straten, & Warmerdam, 2007; Dimidjian et al., 2006; Ekers et al., 2014; 
Mazzucchelli, Kane, & Rees, 2009; Richards et al., 2016). A recent large-scale RCT found 
that the economic benefits of BA are also considerable, as non-inferior clinical outcomes in 
comparison to CBT were achieved at a 21% reduced cost (Richards et al., 2016). However, 
the evidence base for BA is primarily based on individual treatment, with much less focus on 
the acceptability and effectiveness of group BA delivery.   
The importance of understanding the potential of BA as a group therapy relates to its 
delivery as well as its potential effects. BA works by adopting a  ‘outside-in’ treatment 
approach, using pragmatic behavioral techniques to increase access to sources of positive 
reinforcement that in turn then reduce associated depressive thoughts and feelings (Curran et 
al., 2012).  BA is therefore often characterized as a pragmatic and parsimonious treatment for 
depression (Jacobson et al., 1996). As fewer treatment competencies are required, therapists 
can be trained in a relatively short time (Ekers, Richards, McMillan, Bland, & Gilbody, 
2011).  The relative simplicity of BA also makes it well suited to group adaptation, as 
behavioral treatment principles can be easily taught, grasped and implemented (Dimidjian, 
Barrera, Martell, Muñoz, & Lewinsohn, 2011). Investigation of indirect comparisons of BA 
treatment mode have indicated individual and group delivery treatment effects do not differ 
significantly with group BA producing a moderate effect estimate (g = 0.62; Ekers et al., 
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2014). During group treatment, patients can additionally benefit from the peer support, 
normalizing and the learning opportunities created by group dynamics (Yalom & Leszcz, 
2005).  Groups, if acceptable to patients, are also organizationally efficient, as they optimize 
scarce therapeutic resources through low therapist to patient ratios (Kellett, Clarke, & 
Matthews, 2007).  
A meta-analysis of group-based BA effectiveness has been reported recently (Chan, 
Sun, Tam, Tsoi, & Wong, 2017), but had a broad raft of methodological problems.  Only 
seven randomized controlled trials (RCTs) were identified, which does not represent the full 
evidence base of clinical trials of group BA (as will be seen below). Equally importantly, the 
seven studies included were actually individual BA (Carlbring et al., 2013; Dimidjian et al., 
2006; Ekers et al., 2011; Gawrysiak, Nicholas, & Hopko, 2009; Hopko, Lejuez, LePage, 
Hopko, & McNeil, 2003; Moradveisi, Huibers, Renner, Arasteh, & Arntz, 2013; Pagoto et 
al., 2013).  Finally, no mention of treatment acceptability issues was made.  Any clinical 
conclusions concerning group BA drawn from the Chan et al. (2017) meta-analysis are 
therefore seriously flawed.   
This meta-analysis therefore focuses on the acceptability and efficacy of group BA 
compared to standard treatment or waitlist controls and other active therapies and seeks to 
identify key moderators of outcome. Identifying treatment moderators helps to establish 
factors that account for variations in treatment effect (i.e. under what conditions and for 
which patients group BA is most effective). Potential moderators include intervention 
characteristics (such as type of BA model or number of sessions) and patient characteristics 
(such as population and depression severity). If differing BA models are not equally 
effective, it could suggest that different levels of treatment model complexity moderate 
outcome, and can indicate which models may be more suitable to group adaptation. With 
regards to amount of treatment, what is the optimum number of group BA sessions? 
Providing more treatment than required is wasteful of resources, whereas not providing 
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enough treatment risks creating a ‘revolving door’ for therapy services (Hansen, Lambert, & 
Forman, 2002).  The dose-response literature suggests a negatively accelerated association 
between number of sessions and improved outcome, with estimates of 13-18 sessions 
required to achieve a 50% recovery rate (Hansen et al., 2002; Harnett, O’Donovan, & 
Lambert, 2010). However, BA has shown significant reductions in depression after much 
briefer periods of treatment (Armento, McNulty, & Hopko, 2012; Gawrysiak et al., 2009; 
Hopko, Robertson, & Carvalho, 2009). Meta-analytic investigations of the effectiveness of 
psychotherapy for depression has shown limited association with the number of sessions, 
advocating the implementation of briefer treatments (Cuijpers, Huibers, Daniel Ebert, Koole, 
& Andersson, 2013).  
In terms of population-related moderators, which patients are most suitable for group 
BA? Establishing patient suitability is important as the acceptability of BA is based on 
assumed ease of application. It has been suggested that BA may provide a useful treatment 
option for varied and diverse patients, often from underrepresented patient populations 
(Dimidjian et al., 2011). Similarly, patients can present with differing severities of 
depression, but the differential effects of baseline severity on group BA treatment outcome 
are currently unclear. The previous consensus was that severely depressed patients tend to see 
better outcomes when treated with pharmacotherapy, whereas psychotherapy is indicated 
when treating mild to moderate depression (Elkin et al., 1995).  Recently, this consensus has 
been questioned, as numerous studies have been unable to demonstrate baseline severity 
moderating treatment outcome (Driessen, Cuijpers, Hollon, & Dekker, 2010; Weitz et al., 
2015). Thus, psychotherapy appears to be as an appropriate treatment for severe depression.  
BA appears particularly well suited for treating severe depressive phases, as the severely 
depressed patient may be unable to engage in cognitive work, or may indeed find the work a 
depressive trigger due to heightened guilt and self-blame (Dimidjian et al., 2006).     
Ioannidis & Lau (1999) noted that the meta-analytic method was best employed when 
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summarizing, synthesizing and quantifying an evidence base that is made up of extant studies 
with high methodological quality.  As randomized controlled trials (RCTs) champion internal 
as opposed to external validity, then RCTs ensure high methodological quality (Barkham, 
Stiles, Lambert, & Mellor-Clark, 2010). This meta-analysis therefore solely focuses on RCTs 
that have been conducted evaluating the effiacacy of group BA, to ensure that the quantititive 
synthesis was best on the best avaliable evidence.  To summarize, this meta-analysis had 
three aims: (1) assess the efficacy of group BA when compared to passive and active 
controls, in terms of depression outcomes and recovery rates; (2) explore moderators of 
outcome in terms of intervention and patient variables; and (3) define the acceptability of 
group BA by calculating drop-out rates in comparison to passive and active controls.  
Method 
Identification and Selection of Studies  
First, previous meta-analyses of BA were examined and cross-referenced to identify 
any group-based intervention studies.  Second, a comprehensive electronic search was 
conducted, to identify literature published up until October 2016, which was modified for 
each of four databases used (MEDLINE, PsycINFO, Cochrane Library and CINAHL).  
Search terms (expanded using alternative synonyms, and both US and UK spellings) for (i) 
behavioral activation/therapy (including activity scheduling/pleasant events), (ii) depression 
and (iii) treatment efficacy were combined using a mixture of MeSH, title, abstract, keywords 
and text word searches. Filters to human and adult populations were applied (see Appendix A 
for search strategy). Third, reference lists of identified articles and previous BA reviews were 
manually searched to identify any additional studies. The primary reviewer (MSB) screened 
the initial title and abstracts and reviewed the full-texts of all identified studies. Uncertainty 
regarding study eligibility was debated with two other readers (SK and GW) to reach a 
consensus decision.   
Inclusion Criteria  
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RCTs of group BA, with adults aged 18 and over with a depressive disorder or 
elevated symptoms of depression (assessed via a clinical screening interview or self-rated 
symptoms scored above a defined clinical cut-off on a standardized measure of depression). 
There was no limitation in terms of co-morbidity, as long as depression was a primary 
presenting problem. Studies containing child and adolescent participants, individuals with 
intellectual disability and participants with sub-clinical symptoms of depression were 
excluded. The methods of studies were analyzed, and the intervention was labelled BA if, and 
only if, the study delivered a purely behavioral treatment. Studies were labelled BA when the 
treatment focused on the functional analysis of behavior (in the absence of changing 
cognitions) and resultant behavioral change, in the pursuit of increasing positive mood.  
Therefore, mood-activity monitoring, activity scheduling and behavioral activation 
comprised the behavioral treatment components.  The Mazzuchelli et al. (2009) BA treatment 
definitions were used for this review; i) pleasant events (Lewinsohn et al., 1980); ii) self-
control (Rehm, 1984); iii) contextual (Martell et al., 2001) and iv) BATD (Lejuez et al., 
2001). Minimum group size was defined as three or more participants in a group in a study. 
There was no limit on treatment duration or setting. 
Comparators included any passive control, treatment as usual (TAU) or active 
treatment. Control comparators provided patients with a waitlist, TAU consisted of standard 
routine care in clinical practice settings, such as inpatient or Primary Care Physicians/General 
Practitioner care and active treatment comparators were other psychotherapies delivered in a 
therapeutic format that made an additional active attempt to improve depression, including 
cognitive therapy (CT), cognitive behavior therapy (CBT), problem-solving therapy, 
supportive therapy and non-specific psychotherapy. No language restrictions were applied, 
but a publicly available English language translation of the paper was an inclusion criteria.  
Unpublished studies and dissertations were included if available. Those studies that did not 
provide sufficient data to calculate effect sizes were excluded. 
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Outcome Measures  
Primary outcome  
The primary outcome measure was depressive symptomology measured by any 
psychometrically validated self-report or clinician-rated measure. A preferred measures 
hierarchy was used for studies that contained multiple depression outcome measures, so that 
a single effect size per comparison was calculated. Comparisons of self-report and clinician-
rated measures demonstrate that clinician-rated outcomes generate larger effect sizes 
(Cuijpers, Li, Hofmann, & Andersson, 2010). Where studies used both self and clinician 
reported outcomes, self-reported outcomes took precedence in order to allow a more 
conservative estimate of treatment effect. The most commonly used self-report measure (i.e., 
BDI or BDI-II) was selected.  When no self-report measure was available, clinician-rated 
measures were selected; the Hamilton Rating Scale for Depression (HRSD) took precedence.  
Secondary outcomes 
When available, information on drop-out and recovery rates wa  extracted as 
dichotomous data. Drop-out rates were used as a proxy for treatment acceptability.  This was 
defined as the percentage of non-completers during group BA and control conditions. Non-
completers were determined by the original study authors’ definition. Recovery rates were 
the percentage of patients at end of treatment and/or follow-up who scored below the 
specified clinical threshold on the primary outcome measure.  Recovery definition was 
determined by the original study authors’ definition.  
Quality Assessment 
Methodological quality was assessed using the Cochrane Risk of Bias tool (Cochrane 
Collaboration, 2011). Due to difficulties blinding participants and personnel in psychotherapy 
trials, studies were only assessed on four of the risk of bias elements; randomized allocation, 
allocation concealment, blind outcome assessment and data attrition. Each element was rated 
for low, high or unclear risk of bias and each study given a score based on the number of 
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elements meeting criteria of low risk of bias (max score of four; higher scores indicating 
lower risk of bias). The primary author assessed all the studies and an independent rater 
assessed 50%. Inter-rater reliability was calculated using Cohen’s kappa (Cohen, 1960) 
(where .21-.40 = fair agreement; .41-.60 = moderate agreement; .61-.80 = substantial 
agreement; .81-1.0 = almost perfect agreement; Landis & Koch, 1977). The kappa between 
the primary and independent rater was k=.73, indicating substantial agreement. Discrepancies 
in ratings were resolved through discussion to produce a final quality rating for each study.  
Effect Sizes 
Where data were available, outcomes for depression, recovery and drop-out rates 
were extracted at post-treatment and follow-up (8-weeks or the closest possible time point).  
Standardized mean differences (SMDs) and standard error (SE) terms were computed for the 
difference between conditions for each comparison between BA and a comparator condition. 
SMDs (Cohens d) were calculated by subtracting the mean post-treatment score of the 
comparator condition from the mean post-treatment score of the BA intervention and 
dividing the result by the pooled standard deviation (SD) of both conditions post-treatment. 
Due to the risk of small-sample bias, the J correction was applied to convert SMDs to Hedges 
g (Hedges & Olkin, 1985). Effect sizes were interpreted according to Cohen’s criteria, where 
0.2 is indicative of a small effect, 0.5 a moderate effect, and 0.8 a large effect (Cohen, 1992). 
Dichotomous data for recovery and drop-out rates were calculated as odds ratios (OR); (i.e. 
the percentage of recovery or drop-out from group BA in comparison to passive or active 
controls).   
A hierarchical procedure was applied to effect size calculations - means and SDs were 
used wherever possible, followed by effect size data, dichotomous data, and finally t or F-
scores. Controlled studies with sub-groups or multiple arms that were comparable were 
collapsed into one group using Cochrane’s recommended method (Cochrane Collaboration, 
2011). Studies with multiple comparators within one comparison that could not be collapsed 
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were included separately, with the number of participants in the shared intervention group 
split evenly across comparisons. For example, pair-wise comparisons of group BA with both 
CT and non-directive therapy from Shaw (1977) were both entered into the active therapy 
meta-analysis (means and SDs unchanged), with the number of patients who received group 
BA divided out equally between the two, to ensure patients were not included twice 
(Cochrane Collaboration, 2011).   
Meta-analysis  
Data were synthesized using Meta-Essentials (Suurmond, van Rhee, & Hak, 2017). 
Pooled effect sizes and 95% confidence intervals were computed using the inverse of the 
variance to weight the effect estimates (i.e., outcomes in favor of BAG were indicated by a 
positive effect size). Due to the expected level of heterogeneity resulting from different 
comparator types, a random-effects model was used to account for within- and between-study 
variance. Statistical significance was set at an alpha value of 0.05. Heterogeneity was 
investigated using the I2 statistic to indicate percentage of variation and the accompanying Q 
statistic to report the statistical significance. Heterogeneity benchmarks (Higgins, Thompson, 
Deeks, & Altman, 2003) were used to identify low (25%), moderate (50%) and high study 
heterogeneity (75%).  Pooled effect sizes were then converted into numbers needed to treat 
(NNT; Kraemer & Kupfer, 2006). NNT provides an estimate of the number of patients who 
would need to be treated by the group BA intervention to produce one additional beneficial 
outcome over a comparator condition.  
Subgroup and Moderator Analysis  
Sources of heterogeneity within comparisons were investigated using planned 
subgroup and moderator analyses. Subgroup analysis was used to investigate four categorical 
variables: control/therapy type (waitlist/TAU and CBT/other psychotherapy); assessment 
type (clinical interview/elevated symptoms above clinical cut-off); type of BA (pleasant 
events/self-control/contextual/BATD); and population (young adults/adults/older adults). 
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Meta-regression was used to investigate five continuous variables: study quality (0-4 risk of 
bias items); baseline depression (standardized Z-scores); gender (proportion of males); 
number of group sessions and group size. The beta-coefficient significance threshold was 
adjusted to p < 0.01 to account for multiple testing (Thompson & Higgins, 2002), and a 
minimum of 10 studies was required to investigate moderators within comparisons (Cochrane 
Collaboration, 2011). 
Publication Bias  
Where there were sufficient numbers of studies (k > 10), publication bias was 
assessed via visual inspection of asymmetry on a funnel plot of SEs against effect sizes. 
Additional statistical analysis of study distribution asymmetry was undertaken using the 
funnel plot regression method (Macaskill, Walter, & Irwig, 2001). Trim and Fill imputation 
of missing data gave an adjusted estimate effect, accounting for publication bias (Duval & 
Tweedie, 2000).    
Results 
Study Selection 
After the removal of duplicates, searches identified 5335 records to be screened 
(Figure 1). Title and abstract screening identified 78 articles to be retrieved for full-text 
review. Upon review, 59 were excluded (reasons outlined in Figure 1) leaving a total of 20 
studies meeting the inclusion criteria. One remaining study was identified as an outlier and 
excluded [20] from the quantitative synthesis.  This was due to a very large effect size (d = 
5.76) in favor of group BA compared to waitlist.  Removal of this single study was 
conservative and favored the null hypothesis; this was deemed appropriate to reduce the risk 
of over-estimation of overall effect of BA.  
Insert figure 1 here 
Study details and quality ratings are available in Appendix B. Of the N=19 studies 
included, quality ranged from zero to three quality standards met (max four). Overall study 
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quality was poor. In particular, nearly all studies provided unclear descriptions of 
randomization and concealment procedures (see Appendix C for full quality ratings). Only 
one study was classed as high quality (met three or more quality criteria). Eight studies were 
deemed medium quality (met 1-2 quality criteria), while the remaining 11 studies were 
classed as low quality (met 0 quality criteria).  
Meta-analysis of Group BA 
Study characteristics  
Nineteen studies were included across two meta-analytic comparisons. Group BA was 
compared to controls across 13 studies and active therapies in 12 studies across 15 
comparisons. In the control comparisons, nine studies compared BA with a waitlist control 
and four used TAU. TAU consisted of inpatient (N=3) and outpatient (N=1) standard 
treatment, with varying levels of daily to weekly contact during the study period. In the active 
therapy comparisons CBT/CT was the most common comparison psychotherapy (N=5).  The 
treatment comparators included supportive psychotherapy, psychodynamic psychotherapy, 
non-directive psychotherapy, problem-solving and assertiveness training. All comparator 
active therapies were delivered in a group format. Participants were recruited from the 
community (N=10), Universities (N=3) and clinical services (N=6; outpatient N=2, inpatient 
N=4). Depression was diagnosed via clinical interview (N=17) or self-report symptoms 
exceeding a depression measure clinical cut-off (N=2). Depression symptomology was 
assessed via self-report (N=10), clinician report (N=1), or a combination (N=8). The most 
commonly employed self-report outcome measure was the BDI or BDI-II (N=15), and the 
most commonly employed clinician-rated outcome measure was the HRSD (N=7). Follow-up 
duration ranged from 2-32 weeks across N=13 studies.  The mean follow-up period was 6 
weeks.  
BA group studies were conducted on adults in the general population (N=14), 
students (N=3) and older adults (N=2). Mean depression severity at intake ranged between 
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mild (N=6), moderate (N=8) and severe (N=4). One study did not report sufficient 
information to establish baseline severity. Three studies focused on treating a primary 
problem of depression in conjunction with co-morbid disorders (substance abuse and 
anxiety). BA treatment type included pleasant events (N=8), self-control (N=6), contextual 
(N=2) and BATD (N=3). Group sizes ranged from 3-10 participants with a mean of seven, 
treatment duration ranged from 2-12 sessions, with session duration ranging from 30-120 
minutes.  Drop-out rates ranged between 0-33% but were unreported in nine studies.  
Recovery rates ranged from 25-100% but were unreported in 12 studies. Recovery was 
defined by use of clinical cut-offs on measures (N=5) and MDD diagnosis (N=2). Intent-to-
treat analysis was used in N=4 studies, with the remaining 15 studies using completers 
analyses.  
Comparison 1: Group BA versus waitlist/TAU control comparators 
Depression at post-treatment; group BA versus waitlist/TAU    
 Post-treatment outcomes from 13 studies contributed to this analysis, totaling N=461
participants (group BA N=244; control N=217). The overall aggregated SMD was 0.72 (95% 
CI 0.34 to 1.10; Z = 4.15; p<0.0001) in favor of group BA, suggesting a significant moderate 
to large effect (Figure 2). Group BA was effective at reducing depressive symptoms at 
treatment completion, when compared to waitlist and TAU controls. The NNT for group BA 
was 2.57; one out of every three patients experiences additional benefit from group BA when 
compared to controls at treatment completion. There was significant between-study 
heterogeneity contributing to moderate variation in effect (I2 = 58%; Q = 28.72, p=0.004).  
Insert figure 2 and table 1 here 
 Subgroup analysis and meta-regression results are displayed in Table 1. Significant 
variation in effect size was associated with type of control condition. A large effect was 
observed for waitlist controls, but the effect for group BA was small and non-significant 
when compared to TAU. Treatment effects were not significantly affected by assessment 
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method, type of BA or sample population. Moderate heterogeneity was evident in the 
majority of sub-groups. Although not significant, moderating effects of study quality were in 
the direction of more favorable effects for group BA in lower quality studies. Meta-
regression analyses found initial depression severity, gender, number of sessions and group 
size were not associated with improved treatment outcomes.  
Funnel plot inspection gave a slight suggestion of asymmetry (see Appendix D).  This 
indicates that smaller studies may have tended to produce larger effects in favor of group BA. 
The adjusted effect size produced by Trim and Fill imputation of missing data produced a 
slightly smaller moderate effect size (0.65, 95% CI 0.25 to 1.05). Testing the extent of 
asymmetry via funnel plot regression showed sufficient symmetry of study distribution (B = -
0.004, t(11) = -0.76, p=0.47).  
Depression at follow-up; group BA versus waitlist/TAU  
 Four studies (waitlist k=1; TAU k=3) had follow-up comparisons with a total of 
N=129 participants (group BA N=64; control N=65). There was a moderate pooled SMD of 
0.69 (95% CI 0.19 to 1.19; Z = 4.42; p<0.0001) in favor of the maintained effects of group 
BA at follow-up (Figure 2). Group BA therefore appeared effective at sustaining 
improvement at follow-up compared to controls. The NNT was 2.67, indicating that at 
follow-up one out of every three participants experienced additional benefit from group BA 
compared to controls. Studies were statistically homogeneous (I2 = 0%; Q = 2.25, p=0.52), 
even when taking a higher significance level threshold (p<0.1) to account for low power from 
the small number of studies. Limited variance between studies negated the need for further 
heterogeneity analysis. There were an inadequate number of studies (k<10) to test for 
publication bias.  
Recovery and drop-out rates; group BA versus waitlist/TAU  
 Two studies (waitlist k=2) reported recovery rates for 118 participants (group BA 
N=64; control N=54). Recovery rates were significantly higher following group BA than 
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waitlists (group BA 52%, control 28%), producing a significant odds ratio of 2.99 (95% CI 
0.20 to 43.86; Z = 5.17; p = <0.001). More participants recovered after receiving group BA 
than those allocated to a waitlist condition. All studies were statistically homogeneous (I2 = 
0%; Q = 0.25, p = 0.62).  
Five studies (waitlist k=4; TAU k=1) reported drop-out rates for 325 participants 
(group BA N=185; control N=140). There was no difference in drop-out rates between group 
BA (15%) versus control conditions (17%), with a non-significant odds ratio of 0.69 (95% CI 
0.21 to 2.29; Z = 0.86; p = 0.20). Patient drop-out rates were matched across group BA 
(15%), waitlist (18%) and TAU (14%). Between-study variance was minimal and not 
significant (I2 = 24%; Q = 5.26, p = 0.26).  Limited heterogeneity and the small number of 
studies reporting recovery and drop-out outcomes constrained further investigation into 
sources of variation in effect sizes. The number of studies of group BA reporting recovery 
and dropout rates were insufficient to perform any publication bias tests.  
Comparison 2: Group BA versus other active psychotherapies 
Depression at post-treatment in group BA versus other active psychotherapies 
 Post-treatment outcomes from 15 comparisons contributed to this analysis, totaling 
N=526 participants (group BA N=254; active psychotherapies N=272). There was no 
difference in the effect of group BA when compared to other psychotherapies, with a non-
significant SMD of 0.14, tending towards being in favor of group BA (95% CI -0.18 to 0.46; 
Z = 0.87; p = 0.38) (Figure 3). Group BA was as effective at reducing depressive symptoms 
as other active psychotherapies. The NNT for group BA was 12.68.  This indicates one out of 
every 13 participants would experience additional benefit post-treatment from being in a 
group BA treatment, when compared to other psychotherapies. Between-study heterogeneity 
was moderate and significant (I2 = 63%; Q = 38.22, p=0.0005).  
Insert figure 3 and table 2 here 
Further investigation into variations in effect estimate is displayed in Table 2. 
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Subgroup analyses of different psychotherapies found that group BA compared to CBT/CT 
therapies resulted in a minimal non-significant effect. When compared to other 
psychotherapies, group BA resulted in a small (non-significant) effect that leant towards 
favoring it as a treatment. Significantly differing effect sizes were not evident when 
comparing different types of BA or the sample populations (all studies used clinical 
interviews, so assessment type was not assessed as a moderator). There was moderate 
heterogeneity present in most of the subgroups. Meta-regression analyses found limited 
evidence of variation in effect sizes according to study quality, initial depression severity, 
gender, number of sessions or group size.   
Funnel plot inspection did not suggest evidence of asymmetry (see Appendix D), with 
funnel plot regression providing evidence of a symmetrical study distribution (B = 0.005, 
t(14) = 1.09, p=0.30). Trim and Fill imputation estimated one study was missing and 
produced an adjusted overall effect estimate of 0.21 (95% CI -0.18 to 0.61), representing a 
slight increase in favor of group BA, albeit still not reaching significance. The removal of the 
smallest studies reduced the overall effect estimate to 0.08 (95% CI -0.33 to 0.50), indicating 
minimal influence of a small study effect. These observations indicate a minimal effect of 
publication bias and suggest the effect estimate appears reasonably robust.  
Depression at follow-up in group BA versus other active psychotherapies 
 Eight studies performed 10 follow-up comparisons (CBT/CT k=5; other therapy k=5) 
with a total of 240 participants (group BA N=122; active psychotherapies N=118). There was 
a small SMD of 0.32 favoring group BA (see Figure 3), but this was not significant (95% CI -
0.10 to 0.74; Z = 1.50; p = 0.13). Group BA and the other active psychotherapies therefore 
produced similar maintained treatment effects at follow-up. The NNT was 6.16, indicating 
that by follow-up one out of every six patients experienced additional benefit from group BA. 
Significant between-study heterogeneity was observed representing a moderate level of 
variance (I2 = 57%; Q = 21.00, p=0.01). Five comparisons of group BA versus CBT/CT 
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produced similar effects at follow-up (SMD = 0.07; 95% CI -0.41 to 0.55; Z = 0.27; p = 
0.78). BA was compared to other psychotherapies in the remaining five studies at follow-up 
and showed a moderate (but non-significant) effect in favor of group BA (SMD = 0.59; 95% 
CI -0.09 to 1.69; Z = 0.27; p = 0.09). The small number of studies prevented any further 
exploration of moderating variables and publication bias.  
Recovery and drop-out rates during group BA versus other active psychotherapies 
 Seven studies with nine comparisons (CBT/CT k=4; other k=5) reported recovery 
rates for 351 participants (group BA N=169; other psychotherapies N=182). There was no 
difference in recovery rates following group BA compared to other psychotherapies (69% 
during group BA versus 61% during other active psychotherapies) with a non-significant 
odds ratio of 1.30 (95% CI 0.41 to 4.07; Z = 0.44; p = 0.66). The recovery rate for group BA 
was comparable to that of other active psychotherapies. Group BA versus CBT/CT had a 
non-significant OR of 0.39 in favor of CBT/CT (95% CI 0.04 to 4.15; Z = 0.77; p = 0.44).  
Group BA versus all other therapies had a non-significant OR of 2.72 in favor of group BA 
(95% CI 0.83 to 8.85; Z = 1.66; p = 0.10).  The studies were significantly heterogeneous (I2 = 
61%; Q = 20.42, p=0.009), but there were insufficient studies to examine moderators of 
variation in effect size or to test publication bias.  
Seven studies (CBT/CT k=1; other therapy k=6)  reported drop-out rates for 370 
participants (group BA N=206; other psychotherapies N=164). There was no difference 
between drop-out rates during group BA (14%) versus other psychotherapies (17%), with a 
non-significant odds ratio of 0.71 (95% CI 0.37 to 1.34; Z = 1.06; p = 0.29). Between-study 
heterogeneity was minimal and non-significant (I2 = 0%; Q = 5.25, p = 0.51). Subgroup 
analysis of type of psychotherapy (CBT/CT or other psychotherapies) did not result in 
significantly different drop-out rates (CBT/CT OR = 0.62; other psychotherapy OR = 71; p = 
0.89). Further moderator analysis and tests of publication bias were not conducted, due to 
insufficient number of studies. 




The objective of this meta-analysis was to quantify the acceptability and efficacy of 
BA when delivered in groups to treat depression and explore key potential moderators of 
outcome.  To achieve this objective, only RCTs were selected and this enabled a comparison 
to be made with both passive and active controls.  This analysis was conducted in order to 
provide guidance to commissioners and clinicians in terms of offering evidence-based 
treatments for depression. Particularly, this meta-analysis also has provided the first 
scientifically credible quantitative review of the evidence base for group BA, in contrast to 
the review conducted by Chan et al. (2017).  
Summary of group BA outcomes 
In relation to the first aim, the results provide support for the effectiveness of group 
BA in the treatment of depression across trial contexts. Compared to waitlist comparators, 
group BA facilitated significantly reduced depressive symptoms at treatment completion and 
at follow-up, improved recovery rates and equivalent drop-out rates.  One out of every three 
participants would expect to experience additional benefit from receiving group BA, when 
compared to waitlist. When solely compared to TAU, group BA did not add any additional 
benefit, with no significant differences in post-treatment outcomes. Compared to other 
routinely used psychotherapies for depression (including CBT), group BA produced 
equivalent outcomes at treatment completion and at follow-up, with matched recovery and 
dropout rates. The results therefore indicate that group BA offers an acceptable, equivalent 
and useful treatment option in the treatment of depression, both in the short and medium-
term.   
The moderate to large effects in the reduction of depressive symptoms and increased 
clinical recovery rates suggests that BA principles translate well into group format settings. 
The translation of BA theory to group delivery supports the notion that the principles of BA 
remain simple and parsimonious to deliver, regardless of context (Jacobson et al., 1996). The 
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magnitude of the group BA treatment effect compared to controls is similar to the effect 
observed (SMD 0.70-0.87) for individually-delivered BA (Cuijpers et al., 2007; Ekers et al., 
2014; Mazzucchelli et al., 2009) and slightly larger than the Ekers et al. delivery format 
moderator estimate (Ekers et al., 2014). Likewise, the group BA treatment effect is 
comparable to the individual BA versus other treatments effect (SMD 0.13; Cuijpers et al., 
2007). Furthermore, benefits of group BA were still evident at follow-up, suggesting 
durability of outcomes for this behavioral intervention.  Therefore, it is reasonable to 
conclude that allocating to group BA is not detrimental to patient outcome, and that 
participants are as likely to engage in group treatment as individual work.   
The lack of significantly different group BA outcomes compared to TAU is in 
contrast to effects seen for individually delivered BA (Ekers et al., 2014) and suggests TAU 
had a comparatively potent effect in the available studies. All but one of the present TAU 
studies were conducted in inpatient settings, so it may be that features of inpatient routine 
care bear similarities with active treatments and provide sufficient potency that is not 
improved on by group BA. Interestingly, while post-treatment outcomes did not support an 
added benefit of group BA over TAU, the significant follow-up effects of group BA versus 
controls were driven by comparisons with TAU. Although follow-up only comprised four 
studies, a similar pattern (although not quite significant) was seen for post-treatment to 
follow-up outcomes versus non-CBT therapies. It implies that group BA’s advantage over 
these types of treatments may be in providing more durable beneficial effects in a format that 
is simpler to disseminate. 
Moderators of group BA effectiveness 
Analysis of the variation between studies enabled investigation of moderators of 
group BA effectiveness in order to explore factors that contribute to the treatment effect. 
Whilst such moderator analyses highlight the magnitude of treatment effect associated with 
certain patients, treatments and methodological factors, they do not infer causality (Cochrane 
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Collaboration, 2011). In addition, interpretation needs to be undertaken with caution, as some 
subgroup arms only had a small number of studies and the high correlation of some variables 
(e.g., TAU and inpatient settings/BA types) potentially produces unreliable and confounded 
observed effects.  
Group BA was used in studies with a range of participants and varied clinical 
presentations, and the treatment effect when compared to controls or active therapies was not 
related to gender, initial depression severity, assessment method or population. The finding 
that there was no association between the size of treatment effect and initial depression 
severity is in line with extant evidence (Driessen et al., 2010; Weitz et al., 2015), and 
contradicts original conclusions that psychotherapy effects are larger for less severe 
depression (Elkin et al., 1995). The current results imply that, regardless of baseline severity 
of depression, participants can experience benefit from group BA. Behavioral techniques are 
easily grasped and implemented by patients, even when (for example) cognitive functioning 
is impaired during depressed episodes (Lam, Kennedy, McIntyre, & Khullar, 2014). 
Differences between age population subgroups were not significant, but two of the subgroup 
arms were very small for control and the active psychotherapy comparisons. Inspection of the 
size of the effects suggested some variation; group BA was very effective for young adults 
and adults (versus controls), but much less effective in older adults.  It may be the case that 
BA in groups with older adult participants needs to have relevant treatment adaptations 
applied, in order to retain clinical effectiveness (Pasterfield et al., 2014).   
Various treatment delivery factors (group size, type of BA or number of sessions) 
were not associated with differences in effectiveness, when compared against controls or 
active therapy comparisons. Again, statistical interpretation may have been hampered by 
confounding variables and insufficient comparisons in the subgroup arms for types of BA. 
Non-significant variation in effect sizes for different types of BA was evident - simpler 
versions seem to produce the largest treatment effects, but without being statistically 
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superior. However, the majority of the simpler, older protocols were compared to waitlist 
controls, while the newer, more complex protocols were compared to TAU. The lack of a 
definitive advantage of one version of BA highlights that the behavioral treatment model will 
need further refining and testing to determine the optimal conditions for group delivery.  
Number of sessions was not significantly associated with the size of the treatment 
effect - increasing the number of group sessions did not produce better outcomes. This 
finding is in line with Cuijpers et al.’s meta-regression analysis (2013) and supports the 
argument that group BA interventions only need to be brief. Control type did produce 
differences in treatment effects; waitlist comparisons resulted in a large effect, but TAU 
comparisons only had a small beneficial effect in favor of group BA. Similar effects have 
been seen for other types of psychotherapy (Cuijpers, Van Straten, Bohlmeijer, Hollon, & 
Andersson, 2010; Cuijpers et al., 2013) and highlight the importance of the type of 
comparator in determining a relevant estimate of effect.  
Acceptability  
 The low drop-out rate for group BA found in this study (14%) implies BA delivered 
in a group can be well tolerated by patients. A meta-analysis of dropout from one-to-  
treatment for major depression found an overall weighted dropout rate of 20% (Cooper & 
Conklin, 2015). Treatment completion is fundamental to ensure the full benefit of treatment 
is received which is especially pertinent as early termination of psychotherapy is related to 
poorer outcomes (Cahill et al., 2003; Hansen et al., 2002). Any claims of the organizational 
efficiency benefits of group delivery are offset if group attendance is poor.  However, the 
dropout rates observed for group BA in comparison to the active controls (17%) suggests that 
group delivery does not suppress attendance.  The equivalence of the drop-out rates recorded 
supports the notion that BA in a group format is an acceptable treatment and mirrors meta-
analytic findings for individual BA (Ekers, Richards, & Gilbody, 2008). 
Clinical and organizational implications  
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Access to clinically effective group interventions generates a range of organizational 
benefits, in relation to efficient use of facilities, high therapist to patient ratios and potential 
reductions to treatment wait-times (Piper, 2008). Recent evidence (Richards et al., 2016) also 
noted the health economic advantage of BA when delivered on a one-to-  basis.  Demand 
for psychotherapeutic treatment for depression is consistently high, and services can struggle 
to meet this demand whilst simultaneously ensuring high quality care (Kazdin & Blase, 
2011). Frontline depression treatments in clinical services should balance the evidence of 
clinical effectiveness with issues relating to ease of access, acceptability and efficient use of 
scarce resources (i.e., balancing both effectiveness and reach). When evaluating a treatment, 
it is also recommended that it should be compared to the current gold-standard treatment 
(David, Cristea, & Hofmann, 2018). Compared to CBT, BA has an advantage of a potentially 
simpler, shorter training for therapists (or even non-specialists; Ekers et al, 2011). This 
advantage may be particularly relevant in low-income countries, where depression 
contributes highly to the burden of disease but mental health resources are extremely limited 
(Patel, 2012; Richards et al., 2016).  
There were no differences in subgroup clinical outcomes or drop-out rates when 
group BA was compared to group CBT (or CT variations) at post-treatment and follow-up. 
As originally highlighted by Jacobson et al. (1996), this meta-analysis echoes that therapy
focused on changing depressogenic cognitions directly might be therapeutically redundant 
during the treatment of depression. In fact, the comparability of group BA and all other active 
psychotherapy outcomes is consistent with a large body of evidence that suggests all 
therapies are as effective as each other (Cuijpers, 2017). Such findings point to common 
factors shared between therapies producing the treatment benefits (such as therapeutic 
relationship, demand characteristics), rather than the protocol-specific techniques (Wampold, 
2015). If this is the case, it raises questions about CBT as the gold-standard treatment for 
depression. CBT is recommended as the best treatment for depression (National Institute for 
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Health and Clinical Excellence [NICE], 2016), although the evidence does not always 
support that CBT provides treatment effects above and beyond other treatments. In light of 
the potential dissemination and economic advantages of BA over CBT, conducting a non-
inferiority meta-analysis would be a valuable next step.  
The treatment effect estimates produced by this meta-analysis are based on RCT 
evidence, but to what degree do these findings translate into real-world settings? Whilst 
testing the efficacy of group BA using RCTs is of primary importance, it does not necessarily 
indicate how effective such group therapy is when delivered in naturalistic settings 
(Rothwell, 2005).  The internally valid conditions of an RCT (e.g. patient exclusion, therapist 
supervision and treatment fidelity) differ widely from the externally valid conditions of 
routine practice (e.g., the comorbidity of typical patient populations; Seligman, 1995). Whilst 
some evidence suggests the outcomes achieved during routine practice are comparable to 
RCTs (Gibbons et al., 2010; Westbrook & Kirk, 2005), others have found inferior outcomes 
for naturalistic settings (Barkham et al., 2008; Schindler & Hiller, 2010). Whether the 
outcomes recorded here can be replicated in routine practice is currently unclear.  
Limitations  
There is a range of limitations to consider for this meta-analysis. One reviewer 
screened and extracted all the data, which could introduce potential bias in the data. The 
number of BA group studies was limited, with the majority of studies also having relatively 
small sample sizes (Turner, Bird, & Higgins, 2013). For primary outcomes, the number of 
comparisons was suboptimal for most subgroup analyses of post-treatment outcomes and as 
discussed above, the resulting moderator interpretations were somewhat restricted. Even 
fewer studies conducted follow-up depression assessments. The follow-up periods that were 
reported were generally short and so were too brief to provide a truly valid assessment of the 
durability of group BA. The measurement period for follow-up assessments were typically 
between 4-12 weeks and this should be increased to at least one year in future group BA 
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outcome research. As depression has a chronically relapsing nature, whether the effects of 
group BA compared to controls or active therapies can be retained in the long-term is still 
unclear (Steinert, Hofmann, Kruse, & Leichsenring, 2014). Longitudinal tracking of 
outcomes following group BA, relapse rates and any need for further intervention (e.g., 
behavioral ‘top-up’ sessions) would supplement the durability evidence base for group BA. 
Recovery and drop-out data were not widely reported, meaning investigations of moderators 
and publication bias were not possible for those outcomes. Future group BA outcome studies 
should report core information on recovery and drop-out rates as standard and also report 
average session attendance. In terms of future controlled research, then a randomized patient 
preference trial (Howard & Thornicroft, 2006) directly comparing individual versus group 
BA would strengthen the evidence base as indirect comparisons can be confounded by factors 
unrelated to the treatment effect (e.g., different sample populations, comparisons of effects 
versus differing levels of control group rigor; Song et al., 2009). 
The treatment effect reported for group BA in this meta-analysis may be subject to 
risk of some over-estimation and imprecision. First, study quality was poor across all studies 
with only one study deemed to have a low risk of bias.  The effect of study quality was not 
significant, but the lack of variation in study quality meant sub-group analysis had low 
power. In general, the moderating effect of study quality was in the direction of lower quality 
studies producing larger effects in favor of BA. Therefore, the degree of sub-optimal study 
quality may have contributed to an overstated overall treatment effect. It should be noted that 
the Cochrane risk of bias tool was used to aid comparability and consistency of Cochrane 
recommended methods, but it may not be the optimal tool to reflect quality issues in 
psychotherapy research. Use of a quality tool designed specifically for psychotherapy trials, 
such as the Randomized Controlled Trials of Psychotherapy Quality Rating Scale (RCT-
PQRS; Kocsis et al., 2010) may be better suited to capture the most relevant validity factors.  
Second, very few studies analyzed outcomes using the intention-to-treat method and 
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observed effects were mostly based on per protocol analyses. Such ‘completer samples’ are 
again at risk of overestimating treatment effects (Heritier, Gebski, & Keech, 2003). Third, the 
distribution of comparator types across studies was not ideal. With regards to control 
comparisons, the majority were waitlist conditions. Waitlist controls are prone to 
overestimating treatment effects in active comparators (Cuijpers et al., 2010). The large 
difference in the group BA treatment effect compared to waitlists and TAU potentially 
reflects an overstated waitlist effect. It was also noted that the reporting of what TAU 
entailed was often vague, which may have contributed to the heterogeneity detected in the 
studies and makes generalizability of the effect of TAU and group BA similarly difficult to 
interpret. During the active therapy comparisons, the types of other psychotherapies were 
very varied, which might have diluted their effect in comparison to group BA. Only CBT or 
CT treatments were compared in enough studies to allow comparisons by treatment type. 
However, as CBT is the frontline treatment for depression, this allowed subgroup comparison 
of group BA with the current gold-standard (David et al., 2018). Fourth, significant variation 
was evident across BA clinical trials indicating moderate heterogeneity amongst studies, not 
accounted for by the use of a random-effects model or moderator effects. Results give an 
indication of the effectiveness of group BA, but the variability increases the statistical 
imprecision of the effect estimate.  Finally, fewer than half the included studies included a 
treatment integrity check.  This means that group BA might not have been delivered in a 
protocol-adherent way.  
Future research directions 
This evidence shows that group BA is an effective treatment. However, there is no 
single version of BA. Direct comparisons in clinical trials of the different versions of group 
BA are needed to establish the most effective behavioral approach. BA is promoted for its 
simplicity – therefore, adding complexity or extending treatment without improving 
outcomes is counterintuitive and needs testing if it is to be justified. Hence, the focus going 
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forward in the group BA evidence base should be on identifying the most clinically effective 
and organizationally efficient model for BA to be delivered in a group setting and subsequent 
implementation into routine practice. This research could also embed longitudinal measures 
in the method, to allow analysis of what mediates the relationship between BA and outcome.  
Similarly, the suggestion regarding older adults having a poor response to group BA indicates 
that moderators of group BA outcomes (e.g., age) need further investigation. The moderating 
effect of homework compliance on treatment outcomes in relation to other therapies was 
restricted due to lack of data in the present review. Given the crucial link to BA outcome, this 
is an area that would merit additional research. 
Conclusion 
 This review provides support for BA as a standalone treatment for depression, but has 
shown for the first time that a group delivery format can be adopted with confidence. Group 
BA appears to work across a broad population of participants, regardless of depression 
severity. Furthermore, group BA appears as clinically effective and acceptable as CBT, the 
frontline treatment for depression (NICE, 2016). In light of the high and increasing demand 
for depression treatment, BA should be considered as a frontline intervention, on a par with 
CBT. Future research should focus on establishing the optimal delivery, mediators, 
moderators and long-terms effects of group BA, based on high quality efficacy studies and 
assess the degree to which outcomes then translate in routine practice settings.    
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Note: *significant at p < .05 threshold; ** significant at Bonferroni adjusted p < .01 threshold. a P value of Q-statistic as I2 does not have a test of significance; bEffect non-
significant when controlling for control type. Positive effect size indicates in favor of group BA. Abbreviations: TAU: treatment as usual; SMD: standardized mean difference; CI: 
confidence interval; SE: standard error; NNT: Numbers needed to treat; BATD: behavioral ctivation treatment for depression. 
 
 
Subgroup analysis No. of Comparisons SMD (g) 95% CI I
2(%)a P (between subgroups) NNT 
Control type Waitlist 9 1.02** 0.69 to 1.35 32 0.01** 1.89 
 TAU 4 0.20 -0.28 to 0.68 0  8.89 
Assessment method Clinical interview  11 0.75* 0.38 to 1.12 55* 0.72 2.57 
 > clinical cut-off 2 0.53 -0.68 to 1.73 84*  3.42 
BA type Pleasant events 7 1.01** 0.62 to 1.40 4 0.08 1.91 
 Self-control 3 0.87** 0.27 to 1.46 63*  2.17 
 Contextual 1 0.40    -0.64 to 1.44 -  4.49 
 BATD 2 0.00 -0.71 to 0.70 0  - 
Population  Adults general 10 0.81** 0.44 to 1.17 25 0.26 2.31 
 Young adults 2 1.06* 0.24 to 1.89 0  1.83 
 Older adults 1 -0.09 -1.23 to 1.05 -  -19.71 
Meta-regression analysis No. of Comparisons B-coefficient 95% CI SE P NNT 
Quality (risk of bias) (0-4 criteria) 13 -0.31 -0.69 to 0.07 0.18 0.08 - 
Initial depression severity (z scores) 13 0.02 -0.35 to 0.38 0.17 0.93 - 
Gender  (% of males) 13 -0.01 -0.02 to 0.00 0.01 0.08 - 
Number of sessions (2-12 sessions) 13 -0.11 -0.23 to 0.01 0.06 0.05 - 
Group size (3-10 patients) 13 0.02 -0.20 to 0.23 0.10 0.86 - 
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Note: *significant at p < .05 threshold; ** significant at Bonferroni adjusted p < .01 threshold. a P value of Q-statistic as I2 does not have a test of significance. Positive effect size 
indicates in favor of group BA. Abbreviations: CBT/CT: cognitive behavioral therapy/cognitive therapy; SMD: standardized mean difference; CI: confidence nterval; SE: 





Subgroup analysis No. of Comparisons SMD (g) 95% CI I
2(%)a P (between subgroups) NNT 
Therapy type CBT/CT 6 -0.10 -0.59 to 0.39 7 0.22 -17.74 
 Other therapies 9 0.30 -0.10 to 0.70 30  5.95 
BA type Pleasant events 8 0.02 -0.45 to 0.49 11 0.74 88.62 
 Self-control 5 0.23 -0.34 to 0.80 51  7.74 
 Contextual 1 0.75 -0.53 to 2.03 -  2.48 
 BATD 1 0.01 -1.13 to 1.15 -  177.24 
Population  Adults general 11 0.24 -0.13 to 0.62 11 0.53 7.42 
 Young adults 3 -0.12 -0.90 to 0.67 48  -14.79 
 Older adults  1 -0.33 -1.55 to 0.89 -  -5.42 
Meta-regression analysis No. of Comparisons 
B-
coefficient 95% CI SE P NNT 
Quality (risk of bias) (0-4 criteria) 15 -0.39 -0.91 to 0.12 0.24 0.10 - 
Initial depression severity (z scores) 14 -0.43 -1.01 to 0.16 0.30 0.15 - 
Gender  (% of males) 15 0.00 -0.02 to 0.01 0.01 0.62 - 
Number of sessions (4-12 sessions) 15 -0.09 -0.22 to 0.04 0.07 0.17 - 
Group size (3-10 patients) 15 -0.09 -0.31 to 0.13 0.11 0.43 - 
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Figure 2. Forest plot of post-treatment and follow-up depression symptom effect sizes for 








Figure 3. Forest plot of post-treatment and follow-up depression symptom effect sizes for 
group BA versus active treatment. 
 
 
 
 
